GPH.F Stock Analysis
GP
Uncovered
Galmed Pharmaceuticals Ltd is uncovered by Eyestock quantitative analysis.
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
View Section: Eyestock Rating